The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monens...

The present invention relates to methods for enhancing Hypoxia inducible factor- 1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monen...

1. A water-soluble pharmaceutical product in a solid state and true aqueous solutions of said product comprising a) a therapeutically active substance having a low aqueous solubility of less than 1x10 moles/litre and having a high binding affinity to a plasma protein - wherein the term "high binding affinity" means that more than 90% of the active substance is bound to the applied plasma protein in an aqueous medium in spontaneous equilibrium and room temperature; b) a plasma protein fraction in...